PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Price, Quote, News and Overview
NASDAQ:PACB - Nasdaq - US69404D1081 - Common Stock - Currency: USD
PACB Quote, Performance and Key Statistics
0.9218
-0.02 (-2.09%)
The current stock price of PACB is 0.9218 USD. In the past month the price decreased by -15.43%. In the past year, price decreased by -50.71%.
PACB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 17.98 | 148.60B | ||
| DHR | DANAHER CORP | 24.77 | 132.07B | ||
| A | AGILENT TECHNOLOGIES INC | 20.44 | 30.94B | ||
| IQV | IQVIA HOLDINGS INC | 12.12 | 24.16B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 27.54 | 23.22B | ||
| WAT | WATERS CORP | 29.08 | 20.61B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 30.96 | 14.77B | ||
| ILMN | ILLUMINA INC | 24.14 | 12.72B | ||
| TEM | TEMPUS AI INC | N/A | 10.83B | ||
| RVTY | REVVITY INC | 18.12 | 10.73B | ||
| ICLR | ICON PLC | 9.33 | 10.17B | ||
| QGEN | QIAGEN N.V. | 18.28 | 9.09B |
Related stock screener links
About PACB
Company Profile
Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. The company is headquartered in Menlo Park, California and currently employs 575 full-time employees. The company went IPO on 2010-10-27. The company is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinical researchers to resolve genetically complex problems. Its products and technology under development stem from two differentiated core technologies, which include its HiFi long-read sequencing technology and its Sequencing by Binding short-read sequencing technology. Its products address solutions across a set of applications, including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. The company has developed HiFi long-read sequencing based on Single-Molecule Real-Time technology, which detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid molecules. Its Revio, Sequel, Sequel II and Sequel IIe instruments conduct, monitor, and analyze single-molecule biochemical reactions in real time.
Company Info
PACIFIC BIOSCIENCES OF CALIF
1305 O'brien Drive
Menlo Park CALIFORNIA 94025 US
CEO: Christian O. Henry
Employees: 575
Phone: 16505218000
PACIFIC BIOSCIENCES OF CALIF / PACB FAQ
What is the stock price of PACIFIC BIOSCIENCES OF CALIF today?
The current stock price of PACB is 0.9218 USD. The price decreased by -2.09% in the last trading session.
What is the ticker symbol for PACIFIC BIOSCIENCES OF CALIF stock?
The exchange symbol of PACIFIC BIOSCIENCES OF CALIF is PACB and it is listed on the Nasdaq exchange.
On which exchange is PACB stock listed?
PACB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PACIFIC BIOSCIENCES OF CALIF stock?
21 analysts have analysed PACB and the average price target is 2.15 USD. This implies a price increase of 132.84% is expected in the next year compared to the current price of 0.9218. Check the PACIFIC BIOSCIENCES OF CALIF stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PACIFIC BIOSCIENCES OF CALIF worth?
PACIFIC BIOSCIENCES OF CALIF (PACB) has a market capitalization of 276.61M USD. This makes PACB a Micro Cap stock.
How many employees does PACIFIC BIOSCIENCES OF CALIF have?
PACIFIC BIOSCIENCES OF CALIF (PACB) currently has 575 employees.
What are the support and resistance levels for PACIFIC BIOSCIENCES OF CALIF (PACB) stock?
PACIFIC BIOSCIENCES OF CALIF (PACB) has a resistance level at 1.02. Check the full technical report for a detailed analysis of PACB support and resistance levels.
Is PACIFIC BIOSCIENCES OF CALIF (PACB) expected to grow?
The Revenue of PACIFIC BIOSCIENCES OF CALIF (PACB) is expected to grow by 2.04% in the next year. Check the estimates tab for more information on the PACB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PACIFIC BIOSCIENCES OF CALIF (PACB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PACB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PACB, evaluating the profitability, health, valuation and growth aspects
- PACIFIC BIOSCIENCES OF CALIF (PACB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PACIFIC BIOSCIENCES OF CALIF (PACB) Sales and EPS estimates to see what analysts future expectations are.
- PACIFIC BIOSCIENCES OF CALIF (PACB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PACIFIC BIOSCIENCES OF CALIF (PACB) Insider and Institutional Ownership to learn about the owners and their transactions.
- PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Chart to make your own analysis
- PACIFIC BIOSCIENCES OF CALIF (PACB) Latest news and press-releases to stay up to date.
Does PACIFIC BIOSCIENCES OF CALIF (PACB) stock pay dividends?
PACB does not pay a dividend.
When does PACIFIC BIOSCIENCES OF CALIF (PACB) report earnings?
PACIFIC BIOSCIENCES OF CALIF (PACB) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of PACIFIC BIOSCIENCES OF CALIF (PACB)?
PACIFIC BIOSCIENCES OF CALIF (PACB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.79).
What is the Short Interest ratio of PACIFIC BIOSCIENCES OF CALIF (PACB) stock?
The outstanding short interest for PACIFIC BIOSCIENCES OF CALIF (PACB) is 18.06% of its float. Check the ownership tab for more information on the PACB short interest.
PACB Technical Analysis
PACB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PACB. PACB has a bad profitability rating. Also its financial health evaluation is rather negative.
PACB Financial Highlights
Over the last trailing twelve months PACB reported a non-GAAP Earnings per Share(EPS) of -2.79. The EPS decreased by -144.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.41% | ||
| ROE | -717.77% | ||
| Debt/Equity | 7.05 |
PACB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to PACB. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 50.35% and a revenue growth 2.04% for PACB